Aiming to shed last-place rep, Eli Lilly touts its PhIII pipeline and promises a faster game in R&D
Eli Lilly wants you to know that it is determined to lose its rep as a last-place finisher in the race to get new blockbusters …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
